

been implemented,' said Professor Roger G. Finch, President of the European Society for Clinical Microbiology and Infectious Diseases (Basel, Switzerland) and Professor of Infectious Diseases at City Hospital (Nottingham, UK) and the University of Nottingham (Nottingham, UK). 'The Global White Paper...is long overdue and has come at a crucial time.'

The White Paper calls for: more studies to assess the impact of resistance on the health of patients with community acquired respiratory tract infections (RTIs); greater consideration by organizations responsible for resistance control of the factors driving bacterial resistance, including antibiotic use; further education in the prescription of antibiotics for RTIs;

and greater patient involvement in measures to control resistance.

News in Brief was written by  
*Joanne Clough, Joanna Milburn*  
and *Ben Ramster*

## People

### Awards

#### The 2001 Brinker International Awards for Breast Cancer Research

Bert W. O'Malley (Professor and Chairman of the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA) and Jay R. Harris (Chief of Radiation Oncology, Dana-Farber Cancer Institute and Professor of Radiation Oncology, Harvard Medical School, Boston, MA, USA) have been awarded the 2001 Brinker International Awards for Breast Cancer Research. This award was established by the Susan G. Komen Breast Cancer Foundation and recognizes significant advances in basic research concepts or clinical application in the fields of breast cancer research, screening or treatment.

The award for O'Malley recognizes his contributions to research on the pathway and mechanism of steroid hormone action, which has led to the understanding of how the hormones work. This work has had a significant impact on the fields of endocrinology, reproduction, genetic disease, and endocrine cancers of the breast and prostate. He is also a founder of the field of molecular endocrinology as part of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Arts and Sciences, and the American Academy of Microbiology.

Meanwhile, Harris is being recognized for his contributions in the area of clinical evaluation of breast cancer treatments, in particular, radiation therapy and

conservative surgery for early breast cancer. He is Program Director of the Joint Center for Radiation Therapy Residency Program and was an active member of President Clinton's Special Commission on Breast Cancer and served on the National Action Plan for Breast Cancer.

### Appointments

#### Barbara Wallner joins BioTransplant as CSO

BioTransplant (Charlestown, MA, USA) has appointed Barbara Wallner as Chief Scientific Officer. She comes to the company from Point Therapeutics, where she was co-founder and spent five years as Senior Vice-President of R&D and Chief Scientific Officer. Before this, Wallner worked at Immulogic in a variety of positions including Vice-President of Research. She has also previously spent ten years at Biogen leading several research projects. Elliot Lebowitz, Chief Executive Officer of BioTransplant, said 'Barbara brings to BioTransplant substantial expertise in the areas of autoimmune diseases and cancer, which will considerably strengthen our efforts to advance our portfolio of products through the developmental process.'

#### Key appointments at Sequenom

Following the division of Sequenom into the defined business units, Sequenom Genetic Systems and Sequenom Pharmaceuticals, the Sequenom

Pharmaceuticals unit has announced several changes to key management positions.

The Chief Medical Officer for Sequenom (San Diego, CA, USA), Andreas Braun, will now lead the newly formed Sequenom Pharmaceuticals. Braun has been with the company since 1995 and was the architect of the company's disease gene discovery program. Meanwhile, Jay Lichter joins the company as Executive Vice-President of Business Development from being CEO of the new start-up company, XenoPharm. He also co-founded Sequana Therapeutics and previously held management positions at Pfizer and Geneset.

Charles Rodi has also been promoted to Executive Vice-President of Genomics in which he will lead the direction and operation of the company's internal High-Throughput Genotyping Center. Rodi was previously Vice-President of Molecular Biology with the company and has also been Director of the Genome Sequencing Center at Monsanto.

Finally, Richard Macdonald has been promoted to the position of Senior Vice-President of Corporate R&D. Macdonald joined the company in 1998 and has played a leadership role in establishing the company's bioinformatics group and software.

Toni Schuh, President and CEO of Sequenom said: 'Sequenom has established a strong leadership position in the high-throughput genotyping market. We are using our leadership position to build a profitable Genetics Systems business and, in addition, will develop a pharmaceutical business to commercialize proprietary diagnostics and pharmaceutical products.'

#### Two key appointments at Lipocine

Lipocine (Salt Lake City, UT, USA), a drug delivery biotechnology company, has

announced two key management appointments. Srinivasan 'Srin' Venkateshwaran has been named Vice-President of R&D and Steven Krill has been named Vice-President of Technology Development and will report to Venkateshwaran. Venkateshwaran has previously been Executive Director of R&D at Mylan Technologies and Executive Director of Transdermal and Inhalation Research at TheraTech/Watson Labs. Meanwhile, Krill was most recently Associate Director of Pharmaceutical Development at Novartis Pharmaceuticals Corp. and was previously Head of the Pharmaceuticals Center at Abbott Laboratories.

Dr Patel, President and CEO of Lipocine said: 'Srin's proven drug delivery expertise, leadership strengths and track record... [and] his experience in the product/technology partnering area will be valuable to Lipocine's business going forward.' He added 'Steve's strengths include technology/product development, drug discovery support and developability assessment of NCEs and extramural technology licensing [and he] will lead the development of our new technologies/products.'

### Tamar Howson joins BMS

Tamar D. Howson has been appointed to the position of Senior Vice-President, Corporate Development at Bristol-Myers Squibb (BMS; New York, NY, USA) and will be responsible for leading the company's external alliances, licensing and acquisitions. She was previously Senior Vice-President and Director of Business

Development at SmithKline Beecham and also managed SR One, the US\$100 million venture capital fund of SmithKline Beecham. Howson has also served as an independent business consultant and adviser to companies in the US and Europe. She has also been Vice-President, Venture Investments at Johnson Associates (a venture capital company) and Director, Worldwide Business Development and Licensing for Squibb Corp. She also received the Healthcare Businesswomen's Association 'Woman of the Year Award' in 1999.

### New Executive Director for Business Development at Triad Therapeutics

Joel S. Smith has been appointed to the newly created position of Executive Director for Business Development at Triad Therapeutics (San Diego, CA, USA). He will work with Robert Reed, the company's Senior Consultant for Business Development, to form corporate alliances, structure licensing deals and devise business development strategies. Smith was previously Executive Vice-President of Strategic Development and General Council of BioQ, a knowledge management company. Before this, he was an associate at the law firm, Brobeck, Phleger & Harrison LLP, focussing on venture capital, licensing transactions and IPOs for life science and technology companies. Stephen Coutts, President of Triad said: 'His knowledge and experience in finance and legal and strategic development within the life science industry will prove invaluable as we look to negotiate licensing agreements that will

complement our existing suite of structure-based small molecular discovery technologies and strategies.'

### Stephen Naylor leaves the Mayo Clinic to join Beyond Genomics

Stephen Naylor has been appointed to the position of Chief Technology Officer at Beyond Genomics (a NewcoGen venture; Cambridge, MA, USA), and will lead the company's technological development of the gene, protein and metabolite analysis platforms to support its systems biology approach to drug discovery and biomarker identification. Naylor was previously the founding Director of the Biomedical Mass Spectrometry and Functional Proteomics Facility at the Mayo Clinic, as well as being Professor of Biochemistry and Molecular Biology, and Professor of Molecular Pharmacology and Experimental Therapeutics. He also served as Adjunct Professor of Clinical Pharmacology and Biomedical Engineering (Molecular Biophysics) at the Mayo Foundation. N. Stephen Ober, President of Beyond Genomics said: 'We are thrilled to have a world-class scientist like Steve join our team. He brings an exceptionally strong combination of analytical instrument knowledge and equally impressive experience in applied drug discovery and biomarker identification.'

People was written by  
*Rebecca N. Lawrence*

## Managing your references and BioMedNet Reviews

Did you know that you can now download selected search results on BioMedNet Reviews directly into your chosen reference managing software? After performing a search, simply click to select the articles you wish, choose the format required (e.g. EndNote 3.1). The bibliographic details, abstract and link to the full-text article will then download into your desktop reference manager database.

BioMedNet Reviews is available on an institute-wide subscription. If you do not have access to the full-text articles in BioMedNet Reviews, ask your librarian to contact us at [reviews.subscribe@biomednet.com](mailto:reviews.subscribe@biomednet.com)